Spruce Biosciences Inc [NASDAQ: SPRB] price plunged by -39.45 percent to reach at -$0.05.
The one-year SPRB stock forecast points to a potential upside of 89.33. The average equity rating for SPRB stock is currently 3.00, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Spruce Biosciences Inc [SPRB]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SPRB shares is $0.75 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SPRB stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for Spruce Biosciences Inc shares, keeping their opinion on the stock as Perform, with their previous recommendation back on December 11, 2024. The new note on the price target was released on December 11, 2024, representing the official price target for Spruce Biosciences Inc stock. Previously, the target price had yet another drop from $9 to $2, while RBC Capital Mkts kept a Sector Perform rating on SPRB stock. On March 14, 2024, analysts decreased their price target for SPRB shares from 9 to 2.
The Average True Range (ATR) for Spruce Biosciences Inc is set at 0.03, with the Price to Sales ratio for SPRB stock in the period of the last 12 months amounting to 0.68. The Price to Book ratio for the last quarter was 0.12, with the Price to Cash per share for the same quarter was set at 0.92.
SPRB Stock Performance Analysis:
Spruce Biosciences Inc [SPRB] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -35.15. With this latest performance, SPRB shares dropped by -75.24% in over the last four-week period, additionally sinking by -85.60% over the last 6 months – not to mention a drop of -88.80% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SPRB stock in for the last two-week period is set at 19.62, with the RSI for the last a single of trading hit 17.54, and the three-weeks RSI is set at 21.62 for Spruce Biosciences Inc [SPRB]. The present Moving Average for the last 50 days of trading for this stock 0.3012, while it was recorded at 0.1222 for the last single week of trading, and 0.4247 for the last 200 days.
Insight into Spruce Biosciences Inc Fundamentals:
Spruce Biosciences Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.90 and a Current Ratio set at 2.90.
SPRB Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SPRB. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Spruce Biosciences Inc go to 29.61%.
Spruce Biosciences Inc [SPRB] Institutonal Ownership Details
There are presently around $43.08%, or 48.57%% of SPRB stock, in the hands of institutional investors. The top three institutional holders of SPRB stocks are: RIVERVEST VENTURE MANAGEMENT LLC with ownership of 2.94 million shares, which is approximately 7.1449%. CARLYLE GROUP INC., holding 2.9 million shares of the stock with an approximate value of $$1.52 million in SPRB stocks shares; and CARLYLE GROUP INC., currently with $$1.35 million in SPRB stock with ownership which is approximately 6.3488%.
